IRVINE, Calif., May 07, 2024 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of… Continue reading Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results